Zymeworks (ZYME) has released an update.
Zymeworks Inc., a clinical-stage biotechnology company, is set to engage with investors at several prominent conferences, including the Jefferies Global Healthcare Conference, Goldman Sachs Annual Global Healthcare Conference, and Citi’s European Healthcare Conference throughout June 2024. They are aiming to highlight their advancements in novel biotherapeutics for challenging diseases, with a special focus on zanidatamab, their proprietary bispecific antibody for HER2-positive cancers. The company is on the cusp of a potential breakthrough if the FDA grants accelerated approval for zanidatamab as a new treatment option for biliary tract cancer.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
